Table 4.
Entire population | Excluding amiodarone and levothyroxine users | Restricting to euthyroid range excluding amiodarone and levothyroxine users | |||||||
---|---|---|---|---|---|---|---|---|---|
Afib n=92 |
No Afib n=1273 |
p-value | Afib n=72 |
No Afib n=998 |
p-value | Afib n=62 |
No Afib n=911 |
p-value | |
TSH mIU/L | 1.95 (1.36) |
2.00 (3.64) |
0.28 | 1.88 (1.36) |
1.67 (1.7) |
0.06 | 1.63 (0.82) |
1.55 (0.81) |
0.32 |
FT4 ng/dL | 1.19 (0.24) |
1.12 (0.19) |
0.002 | 1.15 (0.23) |
1.08 (0.15) |
<0.001 | 1.13 (0.15) |
1.08 (0.14) |
0.006 |
TT3 ng/dL | 94.6 (24.4) |
99.0 (21.8) |
0.03 | 98.2 (23.3) |
102.7 (20.5) |
0.04 | 99.2 (20.9) |
103.0 (19.6) |
0.10 |
Afib, atrial fibrillation; TSH, thyroid stimulating hormone; FT4, free thyroxine; TT3, total triiodothyronine
One-way ANOVA was performed using log transformed values of each thyroid function test in separate models. See Supplement Table 2 for results of adjusted binary logistic regression analyses